Skip to main content
Premium Trial:

Request an Annual Quote

Aviva Biosciences Pockets $11.8M in Series B Round

NEW YORK, Sept. 23 - Startup biochip company Aviva Biosciences today said it has secured $11.8 million in the first closing of a series B round of private-equity financing.


China Development Industrial Bank, a long-time investor with Aviva, led the round, which brings to $16.8 million invested in Aviva sine 1998. Axon Instruments and Pac-Link Management also took part in the round.


Aviva, based in San Diego, said it will us the money to help it launch a biochip it is developing with Axon that will work with that firm's PatchXpress line of ion channel drug-screening systems.


Two weeks ago, the company hired former Lynx chief Norrie Russell to be its president and CEO. Russell, who quit Lynx in June, was replaced by Kevin Corcoran, Lynx's vice president of operations and a veteran of Applied Biosystems.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.